Preclinical Evaluation of Dihydropyrazole-Cored Positron Emission Tomography (PET) Ligands for Imaging of Receptor-Interacting Serine/Threonine Protein Kinase 1 (RIPK1) in the Brain

被引:1
作者
Li, Wanqing [1 ]
Zhang, Xiaojun [2 ]
Ma, Jie [3 ,4 ]
Zhou, Jingyin [1 ]
Di, Xuan [1 ]
Huang, Donglan [1 ]
Zhou, Kaixiang [5 ]
Zhang, Jinming [2 ]
Wang, Lu [3 ,4 ]
Fu, Hualong [1 ]
Cui, Mengchao [1 ,5 ]
机构
[1] Beijing Normal Univ, Coll Chem, Key Lab Radiopharmaceut, Minist Educ, Beijing 100875, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Dept Nucl Med, Beijing 100853, Peoples R China
[3] Jinan Univ, Ctr Cyclotron & PET Radiopharmaceut, Dept Nucl Med, Guangzhou 510630, Peoples R China
[4] Jinan Univ, Affiliated Hosp 1, PET CT MRI Ctr, Guangzhou 510630, Peoples R China
[5] Beijing Normal Univ Zhuhai, Ctr Adv Mat Res, Zhuhai 519087, Peoples R China
基金
中国国家自然科学基金;
关键词
INFLAMMATION; NECROPTOSIS; INHIBITOR; NECROSTATIN-1; DISCOVERY;
D O I
10.1021/acs.jmedchem.4c01263
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Receptor-interacting serine/threonine protein kinase 1 (RIPK1) has emerged as an important regulator of pathologic cell death and inflammation and is implicated in the pathologies of various central nervous system diseases. In this study, we reported the development of three potent dihydropyrazole-cored RIPK1 positron emission tomography (PET) ligands [F-18]WL1-3. Among these, [F-18]WL1 showed specific binding to RIPK1 in mouse brain sections in vitro through autoradiography and exhibited favorable brain kinetics in mice, characterized by a high initial uptake (brain(2 min) = 4.89% ID/g) and rapid washout (brain(60 min) = 0.21% ID/g). PET studies in rat brains revealed that [F-18]WL1 could readily penetrate the brain with specific binding confirmed by inhibition effects of unlabeled WL1 and GSK ' 547. Notably, [F-18]WL1 showed significant potential in imaging the alterations of RIPK1 in a rat brain of tumor necrosis factor alpha-induced systemic inflammatory response syndrome model. These findings may pave the way for the future design of potent RIPK1 PET ligands.
引用
收藏
页码:16403 / 16415
页数:13
相关论文
共 56 条
[1]  
[Anonymous], 2024, The Human Protein Atlas
[2]  
[Anonymous], 2005, Virtual Computational Chemistry Laboratory
[3]   Life after death: RIP1 and RIP3 move beyond necroptosis [J].
Berger, S. B. ;
Bertin, J. ;
Gough, P. J. .
CELL DEATH DISCOVERY, 2016, 2
[4]   Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase [J].
Berger, S. B. ;
Harris, P. ;
Nagilla, R. ;
Kasparcova, V ;
Hoffman, S. ;
Swift, B. ;
Dare, L. ;
Schaeffer, M. ;
Capriotti, C. ;
Ouellette, M. ;
King, B. W. ;
Wisnoski, D. ;
Cox, J. ;
Reilly, M. ;
Marquis, R. W. ;
Bertin, J. ;
Gough, P. J. .
CELL DEATH DISCOVERY, 2015, 1
[5]   Advances in RIPK1 kinase inhibitors [J].
Chen, Lu ;
Zhang, Xiaoqin ;
Ou, Yaqing ;
Liu, Maoyu ;
Yu, Dongke ;
Song, Zhiheng ;
Niu, Lihong ;
Zhang, Lijuan ;
Shi, Jianyou .
FRONTIERS IN PHARMACOLOGY, 2022, 13
[6]   Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury [J].
Degterev A. ;
Huang Z. ;
Boyce M. ;
Li Y. ;
Jagtap P. ;
Mizushima N. ;
Cuny G.D. ;
Mitchison T.J. ;
Moskowitz M.A. ;
Yuan J. .
Nature Chemical Biology, 2005, 1 (2) :112-119
[7]   Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase [J].
Degterev, A. ;
Maki, J. L. ;
Yuan, J. .
CELL DEATH AND DIFFERENTIATION, 2013, 20 (02) :366-366
[8]   Identification of RIP1 kinase as a specific cellular target of necrostatins [J].
Degterev, Alexei ;
Hitomi, Junichi ;
Germscheid, Megan ;
Ch'en, Irene L. ;
Korkina, Olga ;
Teng, Xin ;
Abbott, Derek ;
Cuny, Gregory D. ;
Yuan, Chengye ;
Wagner, Gerhard ;
Hedrick, Stephen M. ;
Gerber, Scott A. ;
Lugovskoy, Alexey ;
Yuan, Junying .
NATURE CHEMICAL BIOLOGY, 2008, 4 (05) :313-321
[9]   Targeting RIPK1 for the treatment of human diseases [J].
Degterev, Alexei ;
Ofengeim, Dimitry ;
Yuan, Junying .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (20) :9714-9722
[10]   Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties [J].
Ertl, P ;
Rohde, B ;
Selzer, P .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (20) :3714-3717